Literature DB >> 8120687

Abuse potential of various opioid medications.

D Brookoff1.   

Abstract

The abuse potentials of various narcotic medications were assessed by surveying 130 hospital patients who admitted to having abused prescription narcotics within the preceding six months. 85% of the subjects surveyed reported having tried controlled-release narcotic preparations for abuse purposes and 60% reported that they were of little or no use. To obtain another index of abuse potential, the author asked the subjects to estimate the street prices of various medications. The street prices of controlled-release formulations were lower than those of other narcotic medications and those of some uncontrolled nonnarcotic medications. These results suggest that controlled-release narcotic formulations may have a lower potential for abuse than do other narcotic medications. In situations where there is concern about potential abuse or diversion of prescribed narcotics, controlled-release preparations may be an appropriate alternative to high-peaking, rapid-onset opioid formulations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8120687     DOI: 10.1007/bf02598290

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  10 in total

1.  Prescription drug diversion control and medical practice.

Authors:  J R Cooper; D J Czechowicz; R C Petersen; S P Molinari
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

2.  Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations.

Authors:  M Weintraub; S Singh; L Byrne; K Maharaj; L Guttmacher
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

3.  Benzodiazepine prescription regulation. Autonomy and outcome.

Authors:  R M Glass
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

4.  Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities.

Authors:  S G Zullich; T H Grasela; J B Fiedler-Kelly; F M Gengo
Journal:  Ann Pharmacother       Date:  1992-04       Impact factor: 3.154

5.  Undertreatment of medical inpatients with narcotic analgesics.

Authors:  R M Marks; E J Sachar
Journal:  Ann Intern Med       Date:  1973-02       Impact factor: 25.391

6.  Analgesic use in the emergency department.

Authors:  S M Selbst; M Clark
Journal:  Ann Emerg Med       Date:  1990-09       Impact factor: 5.721

7.  Effect of a triplicate prescription law on prescribing of Schedule II drugs.

Authors:  K A Sigler; B G Guernsey; N B Ingrim; A S Buesing; J A Hokanson; E Galvan; W H Doutré
Journal:  Am J Hosp Pharm       Date:  1984-01

8.  Recovery of morphine from a controlled-release preparation. A source of opioid abuse.

Authors:  J C Crews; D D Denson
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

9.  Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation.

Authors:  A Khojasteh; W Evans; R D Reynolds; G Thomas; J J Savarese
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

10.  Treating sickle cell pain like cancer pain.

Authors:  D Brookoff; R Polomano
Journal:  Ann Intern Med       Date:  1992-03-01       Impact factor: 25.391

  10 in total
  5 in total

1.  Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options.

Authors:  Meredith Y Smith; George Woody
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 2.  Five pitfalls in decisions about diagnosis and prescribing.

Authors:  Jill G Klein
Journal:  BMJ       Date:  2005-04-02

Review 3.  Assessing aberrant drug-taking behaviors in the patient with chronic pain.

Authors:  Steven D Passik; Kenneth L Kirsh
Journal:  Curr Pain Headache Rep       Date:  2004-08

Review 4.  Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner.

Authors:  Nalini Vadivelu; Harman Singh-Gill; Gopal Kodumudi; Aaron Joshua Kaye; Richard D Urman; Alan David Kaye
Journal:  Ochsner J       Date:  2014

5.  Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations.

Authors:  Thomas M Tzschentke
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.